Anticholinergic medications are widely used in the treatment of overactive bladder (OAB), as well as for short-term treatment of bladder symptoms following a variety of urologic surgeries. Mounting evidence points to an association between anticholinergic medications and the increased risk of incident dementia. The Society for Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU) thus convened a committee of subject experts to contextualize the current understanding of the cognitive risks of anticholinergic medications in the urologic patient population and to provide practical clinical guidance on this subject.
Statements are based on an expert literature review and the committee's opinion. The document has been reviewed and approved by the SUFU board.
Chronic use (>3 months) of OAB anticholinergic medications is likely associated with an increased risk of new-onset dementia. Short-term (<4 weeks) use of most OAB anticholinergic medications is likely safe in most individuals. Clinicians should consider potential cognitive risks in all patient populations when prescribing OAB anticholinergics for chronic use. Consideration should be given to progressing to advanced therapy (botulinum toxin or neuromodulation) earlier in the OAB treatment paradigm CONCLUSIONS: The current body of literature supports a likely small but significant increased risk of dementia with chronic exposure to OAB anticholinergic medications. Potential harms should be balanced against potential quality of life improvement with treatment.
Neurourology and urodynamics. 2022 Sep 06 [Epub ahead of print]
Jacqueline Zillioux, Blayne Welk, Anne M Suskind, E Ann Gormley, Howard B Goldman
Department of Urology, University of Virginia School of Medicine, Charlottesville, Virginia, USA., Division of Urology, Department of Surgery, Western University, London, Ontario, Canada., Department of Urology, University of California, San Francisco, California, USA., Section of Urology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA., Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA.